Defendant
4 cases as defendant.
Azurity filed an inter partes review petition challenging U.S. 10,828,297 B2, owned by Helsinn, on obviousness grounds. The Board instituted trial on November 19, 2025, and the proceeding remains pending.
Inter partes review petition filed by Azurity Pharmaceuticals against Helsinn Healthcare challenging U.S. Patent No. 9,943,515. The Board instituted review on November 19, 2025, and the proceeding remains pending.
Inter partes review petition filed by Azurity Pharmaceuticals against Helsinn Healthcare challenging U.S. 9,186,357 B2. The proceeding is pending/instituted, with preliminary response and discretionary denial briefing.
Azurity Pharmaceuticals, Inc. filed a petition for inter partes review against Helsinn Healthcare S.A. challenging U.S. Patent No. 8,623,826 B2. The Board instituted review on November 19, 2025, and the proceeding remains pending.